Fiftyone Capital Update, page-28

Good point.

The unique complexities and history of PPS makes it a tough call for outsiders without the technical / legal / scientific knowledge to understand the full implications of manufacturing generics coupled with drug registration requirements in different geographies and the use / approval of the drug for humans versus animals.

I did find this quite informative though - from the FiftyOneCapital 'Deep Dive' in March.


But there is a potential threat - note the use of "may not see any generic competition" in the last sentence.